<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Icosapent ethyl (E-EPA): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Icosapent ethyl (E-EPA): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Icosapent ethyl (E-EPA): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="86689" href="/d/html/86689.html" rel="external">see "Icosapent ethyl (E-EPA): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F15162621"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Vascepa</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F54897964"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Vascepa</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F14717677"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antilipemic Agent, Omega-3 Fatty Acids</li></ul></div>
<div class="block doa drugH1Div" id="F15162678"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> All patients should receive general measures (ie, address modifiable causes, manage atherosclerotic cardiovascular disease [ASCVD] risk, implement lifestyle modification [eg, dietary changes, reduction of alcohol consumption]) and optimal low-density lipoprotein (LDL) lowering therapy for 4 to 12 weeks before considering triglyceride lowering therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34332805']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34332805'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b47722a9-4e94-4e56-bcb1-9c1e4dc667b1">Cardiovascular risk reduction with hypertriglyceridemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiovascular risk reduction with hypertriglyceridemia (adjunctive agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For patients whose triglycerides remain ≥150 mg/dL after general measures and optimal LDL lowering therapy who warrant additional ASCVD risk reduction (ie, those with established ASCVD or diabetes mellitus plus ≥2 risk factors for ASCVD), use icosapent ethyl over other triglyceride lowering therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34332805','lexi-content-ref-30415628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34332805','lexi-content-ref-30415628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 2 g twice daily with meals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34332805','lexi-content-ref-30415628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34332805','lexi-content-ref-30415628'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5fe11c5-5429-4488-93aa-98e687a47477">Hypertriglyceridemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertriglyceridemia (adjunctive agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients whose triglycerides remain ≥500 mg/dL after general measures and optimal LDL lowering therapy who <b>do not</b> warrant additional ASCVD risk reduction, any prescription strength omega-3 fatty acid (including icosapent ethyl) or a fibrate (fenofibrate preferred) is reasonable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34332805']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34332805'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 2 g twice daily with meals.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990004"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied). Eicosapentaenoic acid is not renally eliminated.</p></div>
<div class="block doha drugH1Div" id="F50987243"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F15162679"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F15162630"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Hematologic &amp; oncologic: Hemorrhage (12%; major hemorrhage: 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, atrial flutter, peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gout</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Oropharyngeal pain</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum triglycerides</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain</p></div>
<div class="block coi drugH1Div" id="F15162627"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, anaphylactic reaction) to icosapent ethyl or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F15162628"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: Bleeding, including serious events, has been reported; risk may be increased with concomitant anticoagulant/antiplatelet use. Prolongation of bleeding time not exceeding normal limits has also been observed; use with caution in patients with coagulopathy. Monitor for signs and symptoms of bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fish allergy: Use with caution in patients with known allergy or sensitivity to fish and/or shellfish.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Atrial fibrillation: Atrial fibrillation (AF) or flutter requiring hospitalization may occur; risk increased in patients with a history of AF or flutter.</p>
<p style="text-indent:-2em;margin-left:4em;">• Conditions associated with abnormal lipids: Manage concurrent conditions (eg, diabetes, hypothyroidism, excessive alcohol intake) that may contribute to lipid abnormalities.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Studies have not been conducted in patients with hepatic impairment; however, ALT/AST levels should be monitored periodically during therapy in hepatically-impaired patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Should be used as an adjunct to diet therapy and exercise. Secondary causes of hyperlipidemia should be ruled out prior to therapy. A number of OTC formulations containing omega-3 fatty acids are marketed as nutritional supplements; these do not have FDA-approved indications and may not contain the same amounts of the active ingredient.</p></div>
<div class="block foc drugH1Div" id="F15887579"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vascepa: 0.5 g, 1 g</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 g, 1 g</p></div>
<div class="block geq drugH1Div" id="F15162622"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16570447"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Icosapent Ethyl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 g (per each): $1.97</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $3.14 - $3.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Vascepa Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 g (per each): $2.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $3.55</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F54897965"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vascepa: 1 g</p></div>
<div class="block adm drugH1Div" id="F15162683"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with food. Swallow whole; do not break, crush, dissolve, or chew.</p></div>
<div class="block use drugH1Div" id="F14717568"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiovascular risk reduction with hypertriglyceridemia: </b>As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with triglyceride levels ≥150 mg/dL and either established cardiovascular disease or type 2 diabetes mellitus with ≥2 risk factors for cardiovascular disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertriglyceridemia:</b> As an adjunct to diet to reduce triglyceride levels in adults with severe (≥500 mg/dL) hypertriglyceridemia.</p></div>
<div class="block cyt drugH1Div" id="F15255923"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F15255921"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Icosapent Ethyl may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Icosapent Ethyl may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: Icosapent Ethyl may enhance the antiplatelet effect of Ibrutinib. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F15162624"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adequate intake of omega-3 fatty acids is recommended during pregnancy (IOM 2005; Nordgren 2017). Maternal use of supplements or dietary consumption of omega-3 fatty acids (containing eicosapentaenoic acid and docosahexaenoic acid) influences fetal concentrations (Büyükuslu 2017; Coletta 2010; Miles 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Triglyceride concentrations increase during pregnancy as required for normal fetal development. When increases are greater than expected, supervised dietary interventions that include omega-3 fatty acids may be initiated. In women who develop very severe hypertriglyceridemia and are at risk for pancreatitis, use of prescription omega-3 fatty acid products may be considered (Avis 2009; Berglund 2012; Jacobson 2015; Wong 2015).</p></div>
<div class="block brc drugH1Div" id="F15162626"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 fatty acids are present in breast milk and dietary supplementation may influence milk concentrations (IOM 2005).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F15162650"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take with food. Dietary modification is important in the control of severe hypertriglyceridemia. Maintain standard cholesterol-lowering diet during therapy.</p></div>
<div class="block mop drugH1Div" id="F15162698"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Triglycerides and other lipids (LDL-C) should be monitored at baseline and periodically. In patients with hepatic impairment, monitor ALT and AST periodically during treatment. Signs/symptoms of bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">2013 American College of Cardiology/American Heart Association blood cholesterol guideline recommendations (Stone 2014): Consider evaluation for GI disturbances and skin changes during therapy.</p></div>
<div class="block pha drugH1Div" id="F15162641"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Reduction in the hepatic production of triglyceride-rich very low-density lipoproteins. Possible cellular mechanisms include inhibition of acyl CoA:1,2 diacylglycerol acyltransferase, increased hepatic mitochondrial and peroxisomal beta-oxidation, and a reduction in the hepatic synthesis of triglycerides. The mechanisms contributing to reduction of cardiovascular events are not completely understood but are likely multifactorial (eg, increased eicosapentaenoic acid [EPA] composition from carotid plaques, increased circulating EPA/arachidonic acid ratio, inhibition of platelet aggregation).</p></div>
<div class="block phk drugH1Div" id="F15162643"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: De-esterified to active metabolite (eicosapentaenoic acid [EPA]), which is absorbed in the small intestine.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: ~88 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: EPA is mainly oxidized in the liver similar to fatty acids derived from dietary sources. EPA: minor via CYP-450.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: EPA: ~37 to 89 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: ~5 hours.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F49939754"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Vascepa</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Vascepa</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Vazkepa</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Diabetrics evopax | Epapure</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Vazkepa</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Epapure</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Icosalip</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Vazkepa</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Vazkepa</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Vazkepa</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ansatur | Atheropan | Bioepan | Cislecon | Clessepa | Clessepa choseido | Elmodan | Emeradole | Enazec | Epa ethyl ok | Epacapsoft | Epadel | Epafiel | Epand | Epara | Eparose | Icopent | Icosaate | Iwapent | Lilitto | Lipones | Melbural | Metapass | Metapass fuji | Metapass harasawa | Nasateam | Nonsol | Parjery | Peonal | Searane | Yatorip yoshindo</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Vascepa</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Vazkepa</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Vazkepa</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Vazkepa</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Icosapent ethyl | Vascepa</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Vascepa</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Vazkepa</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-19741526">
<a name="19741526"></a>Avis HJ, Hutten BA, Twickler MT, et al. Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn? <i>Curr Opin Lipidol</i>. 2009;20(6):484-490. doi:10.1097/MOL.0b013e3283319127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icosapent-ethyl-e-epa-drug-information/abstract-text/19741526/pubmed" id="19741526" target="_blank">19741526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21683321">
<a name="21683321"></a>Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, Placebo-controlled, Randomized, Double-blind, 12-week study With an Open-label Extension [Marine] Trial. <i>Am J Cardiol.</i> 2011;108(5):682-690.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icosapent-ethyl-e-epa-drug-information/abstract-text/21683321/pubmed" id="21683321" target="_blank">21683321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22962670">
<a name="22962670"></a>Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2012;97(9):2969-2689.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icosapent-ethyl-e-epa-drug-information/abstract-text/22962670/pubmed" id="22962670" target="_blank">22962670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30415628">
<a name="30415628"></a>Bhatt DL, Steg PG, Miller M, et al; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. <i>N Engl J Med.</i> 2019;380(1):11-22. doi:10.1056/NEJMoa1812792<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icosapent-ethyl-e-epa-drug-information/abstract-text/30415628/pubmed" id="30415628" target="_blank">30415628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28987719">
<a name="28987719"></a>Büyükuslu N, Ovalı S, Altuntaş ŞL, Batırel S, Yiğit P, Garipağaoğlu M. Supplementation of docosahexaenoic acid (DHA) / Eicosapentaenoic acid (EPA) in a ratio of 1/1.3 during the last trimester of pregnancy results in EPA accumulation in cord blood. <i>Prostaglandins Leukot Essent Fatty Acids</i>. 2017;125:32-36. doi:10.1016/j.plefa.2017.08.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icosapent-ethyl-e-epa-drug-information/abstract-text/28987719/pubmed" id="28987719" target="_blank">28987719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21364848">
<a name="21364848"></a>Coletta JM, Bell SJ, Roman AS. Omega-3 Fatty Acids and Pregnancy. <i>Rev Obstet Gynecol</i>. 2010;3(4):163-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icosapent-ethyl-e-epa-drug-information/abstract-text/21364848/pubmed" id="21364848" target="_blank">21364848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>IOM (Institute of Medicine). <i>Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids</i>. The National Academies Press; 2005.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26699442">
<a name="26699442"></a>Jacobson TA, Maki KC, Orringer CE, et al; NLA Expert Panel. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. <i>J Clin Lipidol</i>. 2015;9(6)(suppl):S1-S122.e1. doi:10.1016/j.jacl.2015.09.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icosapent-ethyl-e-epa-drug-information/abstract-text/26699442/pubmed" id="26699442" target="_blank">26699442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21849598">
<a name="21849598"></a>Miles EA, Noakes PS, Kremmyda LS, et al, The Salmon in Pregnancy Study: Study Design, Subject Characteristics, Maternal Fish and Marine N-3 Fatty Acid Intake, and Marine N-3 Fatty Acid Status in Maternal and Umbilical Cord Blood. <i>Am J Clin Nutr</i>. 2011;94(6)(suppl):1986-1992.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icosapent-ethyl-e-epa-drug-information/abstract-text/21849598/pubmed" id="21849598" target="_blank">21849598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21502576">
<a name="21502576"></a>Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and Cardiovascular Disease: A Scientific Statement from the American Heart Association. <i>Circulation</i>. 2011;123(20):2292-2233.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icosapent-ethyl-e-epa-drug-information/abstract-text/21502576/pubmed" id="21502576" target="_blank">21502576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28245632">
<a name="28245632"></a>Nordgren TM, Lyden E, Anderson-Berry A, Hanson C. Omega-3 fatty acid intake of pregnant women and women of childbearing age in the United States: potential for deficiency? <i>Nutrients</i>. 2017;9(3).pii:E197. doi:10.3390/nu9030197<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icosapent-ethyl-e-epa-drug-information/abstract-text/28245632/pubmed" id="28245632" target="_blank">28245632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24222016">
<a name="24222016"></a>Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(25)(suppl 2):S1-S45. doi:10.1161/01.cir.0000437738.63853.7a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icosapent-ethyl-e-epa-drug-information/abstract-text/24222016/pubmed" id="24222016" target="_blank">24222016</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Vascepa (icosapent ethyl) [prescribing information]. Bridgewater, NJ: Amarin Pharma Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34332805">
<a name="34332805"></a>Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology solution set oversight committee. <i>J Am Coll Cardiol.</i> 2021;78(9):960-993. doi:10.1016/j.jacc.2021.06.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icosapent-ethyl-e-epa-drug-information/abstract-text/34332805/pubmed" id="34332805" target="_blank">34332805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27512474">
<a name="27512474"></a>Wong B, Ooi TC, Keely E. Severe gestational hypertriglyceridemia: a practical approach for clinicians. <i>Obstet Med</i>. 2015;8(4):158-167. doi:10.1177/1753495X15594082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/icosapent-ethyl-e-epa-drug-information/abstract-text/27512474/pubmed" id="27512474" target="_blank">27512474</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 86044 Version 139.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
